Search Result

Results for "

GLPG

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADAMTS (1) Adrenergic Receptor (1) Androgen Receptor (2) Autophagy (2) Bcr-Abl (1) CFTR (6) Discoidin Domain Receptor (1) Drug Isomer (1) Free Fatty Acid Receptor (2) GPR84 (1) HBV (1) HIV (3) Integrin (2) Interleukin Related (1) IRAK (2) Isotope-Labeled Compounds (1) JAK (8) LIM Kinase (LIMK) (1) LPL Receptor (1) MAP3K (1) p38 MAPK (1) Phosphodiesterase (PDE) (2) Reference Standards (4) RIP kinase (1) Salt-inducible Kinase (SIK) (3) Src (1) TGF-β Receptor (1) TNF Receptor (2)
By Research Areas:	Cancer (7) Infection (1) Inflammation/Immunology (15) Metabolic Disease (3) Neurological Disease (3)

By Targets:

ADAMTS (1)

Adrenergic Receptor (1)

Androgen Receptor (2)

Autophagy (2)

Bcr-Abl (1)

CFTR (6)

Discoidin Domain Receptor (1)

Drug Isomer (1)

Free Fatty Acid Receptor (2)

GPR84 (1)

HBV (1)

HIV (3)

Integrin (2)

Interleukin Related (1)

IRAK (2)

Isotope-Labeled Compounds (1)

JAK (8)

LIM Kinase (LIMK) (1)

LPL Receptor (1)

MAP3K (1)

p38 MAPK (1)

Phosphodiesterase (PDE) (2)

Reference Standards (4)

RIP kinase (1)

Salt-inducible Kinase (SIK) (3)

Src (1)

TGF-β Receptor (1)

TNF Receptor (2)

By Research Areas:

Cancer (7)

Infection (1)

Inflammation/Immunology (15)

Metabolic Disease (3)

Neurological Disease (3)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12940

GLPG0974 15+ Cited Publications	Free Fatty Acid Receptor	Metabolic Disease
GLPG0974 is a free fatty acid receptor-2 (FFA2/GPR43) antagonist with an IC₅₀ of 9 nM.

HY-18300

Filgotinib Maximum Cited Publications 25 Publications Verification GLPG0634	JAK HIV	Cancer
Filgotinib (GLPG0634) is a selective, orally available JAK1 inhibitor with anti-inflammatory and antiviral activities. Filgotinib can effectively inhibit the activities of JAK1, JAK2, JAK3 and TYK2 with IC₅₀ values of 10 nM, 28 nM, 810 nM and 116 nM, respectively. Filgotinib also inhibits HIV-1 driven gene transcription and reduces proliferation of HIV-1 infected cells. Filgotinib can be used in the study of rheumatoid arthritis and inflammatory bowel disease .

HY-135303

GLPG1205 5+ Cited Publications	GPR84	Inflammation/Immunology
GLPG1205 is potent, selective and orally active GPR84 (a G-protein-coupled receptor) antagonist with a favorable PK/PD profile. GLPG1205 has anti-inflammatory activity and is used for the treatment of pulmonary fibrosis . GLPG1205 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-100506

GLPG0187 15+ Cited Publications	Integrin	Cancer
GLPG0187 is a broad spectrum integrin receptor antagonist with antitumor activity; inhibits α_vβ₁-integrin with an IC₅₀ of 1.3 nM . GLPG0187 inhibits migrasome biogenesis without cytotoxicity .

HY-101772

Ziritaxestat 5+ Cited Publications GLPG1690	Phosphodiesterase (PDE)	Inflammation/Immunology
Ziritaxestat (GLPG1690) is a first-in-class autotaxin (ATX) inhibitor, with an IC₅₀ of 131 nM and a K_i of 15 nM .

HY-150203

GLPG3970	Salt-inducible Kinase (SIK)	Inflammation/Immunology
GLPG3970 (compound 88) is a first-in-class SIK2/SIK3 inhibitor. GLPG3970 can be used for the research of inflammation and autoimmune disease .

HY-137430

Aldumastat 1 Publications Verification GLPG1972; S201086	ADAMTS	Metabolic Disease
Aldumastat (GLPG1972; S201086) is a potent, seletive and orally active ADAMTS-5 (IC₅₀=19 nM) inhibitor, and has 8-fold seletivity over ADAMTS-4 (IC₅₀=156 nM). Aldumastat has anticatabolic activity and is used for osteoarthritis research .

HY-16755

Solcitinib 3 Publications Verification GSK-2586184; GLPG-0778	JAK	Inflammation/Immunology
Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC₅₀ of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively; Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis.

HY-139310

GLPG2938	LPL Receptor	Others
GLPG2938 is a potent and selective S1P2 antagonist. GLPG2938 can be used for the research of idiopathic pulmonary fibrosis .

HY-111099

GLPG1837 2 Publications Verification ABBV-974	CFTR Autophagy	Others
GLPG1837 is a potent and reversible CFTR potentiator, with EC₅₀s of 3 nM and 339 nM for F508del and G551D CFTR, respectively.

HY-157442

GLPG3312	Salt-inducible Kinase (SIK) Discoidin Domain Receptor RIP kinase LIM Kinase (LIMK) MAP3K Bcr-Abl Src TGF-β Receptor	Inflammation/Immunology
GLPG3312 (Compound 28) is an orally active SIK inhibitor with IC₅₀ values of 2.0 nM, 0.7 nM and 0.6 nM for SIK1, SIK2 and SIK3, respectively. GLPG3312 exhibits anti-inflammatory and immunomodulatory activity in vitro on human primary myeloid cells and in vivo in mouse models. GLPG3312 has good oral bioavailability and can be used for research on inflammatory and immune diseases .

HY-111111

Galicaftor 1 Publications Verification ABBV-2222; GLPG-2222	CFTR	Inflammation/Immunology
Galicaftor (ABBV-2222; GLPG-2222) is a potent and orally active cystic fibrosis transmembrane conductance regulator (CFTR) corrector. Galicaftor can be used for cystic fibrosis research .

HY-18300A

Filgotinib maleate Maximum Cited Publications 25 Publications Verification GLPG0634 maleate	JAK HIV	Inflammation/Immunology
Filgotinib maleate (GLPG0634 maleate) is a selective, orally available JAK1 inhibitor with anti-inflammatory and antiviral activities. Filgotinib maleate can effectively inhibit the activities of JAK1, JAK2, JAK3 and TYK2 with IC₅₀ values of 10 nM, 28 nM, 810 nM and 116 nM, respectively. Filgotinib maleate also inhibits HIV-1 driven gene transcription and reduces proliferation of HIV-1 infected cells. Filgotinib maleate can be used in the study of rheumatoid arthritis and inflammatory bowel disease .

HY-175479

GLPG4970	Salt-inducible Kinase (SIK) TNF Receptor Interleukin Related	Inflammation/Immunology
GLPG4970 is a potent, selective and orally active salt-inducible kinase 2/3 (SIK2/SIK3) dual inhibitor with IC₅₀ values of 0.3 nM and 0.7 nM. GLPG4970 has weak inhibition of hERG channel with an IC₅₀ of 29 μM. GLPG4970 can decrease TNFα release and increase IL-10 release GLPG4970 can be used for the researches of inflammation and immunology, such as colitis .

HY-18102

GLPG0492 5+ Cited Publications	Androgen Receptor	Neurological Disease
GLPG0492 is an orally active, non-steroidal selective androgen receptor modulator. GLPG0492 exerts functional transactivation by binding to the ligand-binding domain of the receptor, exhibiting preferential partial agonist activity in muscle and bone tissues with low activity in reproductive tissues. GLPG0492 effectively counteracts muscle atrophy-related pathways, significantly enhances muscle strength, maintains motor ability, reduces fibrosis and improves electrophysiological parameters. GLPG0492 prevents immobilization-induced muscle atrophy and regulates muscle mass homeostasis, serving as a valuable tool compound for studies on Duchenne muscular dystrophy, muscle loss and various types of disuse musculoskeletal atrophy .

HY-156961

Cadefrecitinib GLPG3667	JAK	Inflammation/Immunology
Cadefrecitinib (GLPG3667) is a reversible, ATP-competitive and orally active TYK2 inhibitor with an IC₅₀ of 2.3 nM. Cadefrecitinib inhibits IFNα/pSTAT1, and the IC₅₀ values in human peripheral blood mononuclear cell (PBMC) and whole blood assays are 70 nM and 623 nM, respectively. Cadefrecitinib has the potential for the study of inflammatory and autoimmune diseases .

HY-136990

GLPG0259	p38 MAPK	Cancer
GLPG0259 is a ATP-competitive inhibitor of MAPK-activated protein kinase 5 (MK5) with oral activity. GLPG0259 reduces inflammation and bone destruction in a mouse model of collagen-induced arthritis. GLPG0259 also inhibited the metastasis of prostate cancer (PCa) cells .

HY-153224

GLPG2534	IRAK	Inflammation/Immunology
GLPG2534 is an orally active and selective IRAK4 inhibitor, with IC₅₀ values of 6.4 nM and 3.5 nM for human and mouse IRAK4. GLPG2534 can be used for the research of inflammatory skin diseases .

HY-109152

Navocaftor 1 Publications Verification GLPG 3067; ABBV-3067	CFTR	Others
Navocaftor (GLPG 3067), as a cystic fibrosis transmembrane regulator (CFTR), is a protein modulator (US 20200377491 Al, example 1) .

HY-119936

GLPG2451	CFTR Autophagy	Inflammation/Immunology
GLPG2451 is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, which effectively potentiates low temperature rescued F508del CFTR with an EC₅₀ of 11.1 nM .

HY-12940A

*(S)-GLPG0974*	Free Fatty Acid Receptor	Metabolic Disease
(S)-GLPG0974 is the isomer of GLPG0974 (HY-12940), and can be used as an experimental control. GLPG0974 is a free fatty acid receptor-2 (FFA2/GPR43) antagonist with an IC₅₀ of 9 nM.

HY-158144

GLPG2737	CFTR	Others
GLPG2737 is a potent CFTR type 2 corrector, and GLPG2737 can be used in combination with a type 1 co-corrector in the study of cystic fibrosis .

HY-13961

GLPG0634 analog	JAK	Cancer
GLPG0634 analog (Compoun 176) is a broad spectrum JAK inhibitor with IC₅₀ values of <100 nM against JAK1, JAK2 and JAK3 .

HY-18300R

Filgotinib (Standard) GLPG0634 (Standard)	Reference Standards JAK	Cancer
Filgotinib (Standard) is the analytical standard of Filgotinib. This product is intended for research and analytical applications. Filgotinib (GLPG0634) is a selective and orally active JAK1 inhibitor with IC₅₀ of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

HY-18102A

GLPG0492 (R enantiomer)	Drug Isomer Androgen Receptor	Neurological Disease
GLPG0492 R enantiomer is the R enantiomer of GLPG0492. GLPG0492 is an orally active, non-steroidal selective androgen receptor modulator.

HY-178012

GLPG4471	IRAK TNF Receptor	Inflammation/Immunology
GLPG4471 is a selective and orally active IRAK4 inhibitor with an IC₅₀ of 1.7 nM. GLPG4471 exhibits potent inhibition of cytokine (TNFα and IFNα) secretion in cellular and whole blood phenotypic assays. GLPG4471 displays significant activity in a mouse model of collagen-induced arthritis. GLPG4471 can be used for the study of arthritis .

HY-18300S

Filgotinib-d4 GLPG0634-d₄	JAK	Cancer
Filgotinib-d₄ is the deuterium labeled Filgotinib. Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

HY-133013

GLPG-3221	CFTR	Inflammation/Immunology
GLPG-3221 is a potent, orally active corrector of CFTR (cystic fibrosis transmembrane conductance regulator), with an EC₅₀ of 105 nM. GLPG-3221 can be uesd for the treatment of cystic fibrosis .

HY-18300AR

Filgotinib maleate (Standard) GLPG0634 maleate (Standard)	JAK HIV Reference Standards	Inflammation/Immunology
Filgotinib (maleate) (Standard) is the analytical standard of Filgotinib (maleate). This product is intended for research and analytical applications. Filgotinib maleate (GLPG0634 maleate) is a selective, orally available JAK1 inhibitor with anti-inflammatory and antiviral activities. Filgotinib maleate can effectively inhibit the activities of JAK1, JAK2, JAK3 and TYK2 with IC50 values of 10 nM, 28 nM, 810 nM and 116 nM, respectively. Filgotinib maleate also inhibits HIV-1 driven gene transcription and reduces proliferation of HIV-1 infected cells. Filgotinib maleate can be used in the study of rheumatoid arthritis and inflammatory bowel disease .

HY-18102BS

GLPG0492-13C,d3 racemate	Isotope-Labeled Compounds Adrenergic Receptor	Neurological Disease
GLPG0492- ¹³C,d₃ racemate is ¹³C-labeled GLPG0492 (racemate) (HY-18102B). GLPG0492 racemate is an orally active, non-steroidal selective androgen receptor modulator. GLPG0492 racemate exerts functional transactivation by binding to the ligand-binding domain of the receptor, exhibiting preferential partial agonist activity in muscle and bone tissues with low activity in reproductive tissues. GLPG0492 racemate effectively counteracts muscle atrophy-related pathways, significantly enhances muscle strength, maintains motor ability, reduces fibrosis and improves electrophysiological parameters. GLPG0492 racemate prevents immobilization-induced muscle atrophy and regulates muscle mass homeostasis, serving as a valuable tool compound for studies on Duchenne muscular dystrophy, muscle loss and various types of disuse musculoskeletal atrophy .

HY-101772R

Ziritaxestat (Standard) GLPG1690 (Standard)	Reference Standards Phosphodiesterase (PDE)	Inflammation/Immunology
Ziritaxestat (Standard) is the analytical standard of Ziritaxestat. This product is intended for research and analytical applications. Ziritaxestat (GLPG1690) is a first-in-class autotaxin (ATX) inhibitor, with an IC50 of 131 nM and a Ki of 15 nM .

HY-181347

GLPG3808	HBV	Infection
GLPG3808 is an orally active PAPD5/7 inhibitor. GLPG3808 inhibits the expression of HBcAg in various cells infected with HBV. GLPG3808 reduces the hepatitis B surface antigen levels in HBV-infected animal models. GLPG3808 can be used for the research of hepatitis B virus infection .

HY-100506R

GLPG0187 (Standard)	Integrin Reference Standards	Cancer
GLPG0187 (Standard) is the analytical standard of GLPG0187 (HY-100506). This product is intended for research and analytical applications. GLPG0187 is a broad spectrum integrin receptor antagonist with antitumor activity; inhibits αvβ1-integrin with an IC50 of 1.3 nM . GLPG0187 inhibits migrasome biogenesis without cytotoxicity .

Cat. No.	Product Name	Chemical Structure

HY-18300S

Filgotinib-d4
Filgotinib-d₄ is the deuterium labeled Filgotinib. Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

HY-18102BS

GLPG0492-13C,d3 racemate
GLPG0492- ¹³C,d₃ racemate is ¹³C-labeled GLPG0492 (racemate) (HY-18102B). GLPG0492 racemate is an orally active, non-steroidal selective androgen receptor modulator. GLPG0492 racemate exerts functional transactivation by binding to the ligand-binding domain of the receptor, exhibiting preferential partial agonist activity in muscle and bone tissues with low activity in reproductive tissues. GLPG0492 racemate effectively counteracts muscle atrophy-related pathways, significantly enhances muscle strength, maintains motor ability, reduces fibrosis and improves electrophysiological parameters. GLPG0492 racemate prevents immobilization-induced muscle atrophy and regulates muscle mass homeostasis, serving as a valuable tool compound for studies on Duchenne muscular dystrophy, muscle loss and various types of disuse musculoskeletal atrophy .

GLPG0492-13C,d3 racemate

GLPG0492- ¹³C,d₃ racemate is ¹³C-labeled GLPG0492 (racemate) (HY-18102B). GLPG0492 racemate is an orally active, non-steroidal selective androgen receptor modulator. GLPG0492 racemate exerts functional transactivation by binding to the ligand-binding domain of the receptor, exhibiting preferential partial agonist activity in muscle and bone tissues with low activity in reproductive tissues. GLPG0492 racemate effectively counteracts muscle atrophy-related pathways, significantly enhances muscle strength, maintains motor ability, reduces fibrosis and improves electrophysiological parameters. GLPG0492 racemate prevents immobilization-induced muscle atrophy and regulates muscle mass homeostasis, serving as a valuable tool compound for studies on Duchenne muscular dystrophy, muscle loss and various types of disuse musculoskeletal atrophy .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: